trial
as of 2026-07-01Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
NCTId NCT01658150
at a glance
— · Completed
Enrollment 11 (actual)
Sponsored by Icahn School of Medicine at Mount Sinai
Primary completion 2018-01-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Completed
Enrollment
11 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-09
Primary completion
2018-01-02
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Sponsors
Icahn School of Medicine at Mount SinaiLead Sponsor
Brain & Behavior Research FoundationCollaborator
Investigators
1
Katherine Burdick, PhDPrincipal Investigator
Sites
1 total
New York, United States
Facts & assertions
4 sourced
Enrollment
11
Phase
NA
Primary Completion Date
2018-01-02
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
investigator
person